Stryker Corporation (SYK) is Marshall & Sullivan Inc. WA’s 6th Largest Position

Marshall & Sullivan Inc. WA lessened its position in Stryker Corporation (NYSE:SYK) by 2.1% in the fourth quarter, HoldingsChannel.com reports. The fund owned 30,189 shares of the medical technology company’s stock after selling 655 shares during the quarter. Stryker makes up approximately 3.7% of Marshall & Sullivan Inc. WA’s holdings, making the stock its 6th largest holding. Marshall & Sullivan Inc. WA’s holdings in Stryker were worth $4,674,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the business. WFG Advisors LP grew its stake in Stryker by 1.6% in the second quarter. WFG Advisors LP now owns 2,041 shares of the medical technology company’s stock valued at $283,000 after acquiring an additional 32 shares during the period. Advisory Services Network LLC grew its stake in Stryker by 1.8% in the second quarter. Advisory Services Network LLC now owns 3,398 shares of the medical technology company’s stock valued at $472,000 after acquiring an additional 59 shares during the period. Linscomb & Williams Inc. grew its stake in Stryker by 1.2% in the second quarter. Linscomb & Williams Inc. now owns 10,486 shares of the medical technology company’s stock valued at $1,455,000 after acquiring an additional 121 shares during the period. Scotia Capital Inc. boosted its position in shares of Stryker by 4.5% during the second quarter. Scotia Capital Inc. now owns 5,590 shares of the medical technology company’s stock valued at $776,000 after buying an additional 243 shares during the last quarter. Finally, Ramsay Stattman Vela & Price Inc. boosted its position in shares of Stryker by 0.7% during the third quarter. Ramsay Stattman Vela & Price Inc. now owns 47,418 shares of the medical technology company’s stock valued at $6,734,000 after buying an additional 315 shares during the last quarter. 74.49% of the stock is owned by hedge funds and other institutional investors.

Several research analysts recently issued reports on SYK shares. Zacks Investment Research raised Stryker from a “sell” rating to a “hold” rating in a research report on Tuesday, October 24th. Robert W. Baird reaffirmed a “hold” rating and set a $161.00 target price on shares of Stryker in a research report on Friday, October 27th. Piper Jaffray Companies reaffirmed a “buy” rating and set a $156.00 target price on shares of Stryker in a research report on Friday, October 27th. Wells Fargo & Co lifted their target price on Stryker from $160.00 to $166.00 in a research report on Friday, October 27th. Finally, Stifel Nicolaus lifted their target price on Stryker from $158.00 to $168.00 and gave the company a “buy” rating in a research report on Friday, October 27th. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and fourteen have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $162.50.

Shares of Stryker Corporation (SYK) opened at $159.87 on Monday. The company has a market capitalization of $59,894.02, a price-to-earnings ratio of 24.63, a P/E/G ratio of 2.30 and a beta of 0.70. Stryker Corporation has a fifty-two week low of $125.12 and a fifty-two week high of $170.00. The company has a current ratio of 2.29, a quick ratio of 1.59 and a debt-to-equity ratio of 0.66.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Tuesday, January 30th. The medical technology company reported $1.96 EPS for the quarter, topping the Zacks’ consensus estimate of $1.95 by $0.01. The business had revenue of $3.47 billion for the quarter, compared to analyst estimates of $3.42 billion. Stryker had a return on equity of 24.56% and a net margin of 8.20%. Stryker’s quarterly revenue was up 9.9% compared to the same quarter last year. During the same period last year, the company posted $1.78 earnings per share. analysts anticipate that Stryker Corporation will post 7.12 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Monday, April 30th. Investors of record on Thursday, March 29th will be issued a dividend of $0.47 per share. The ex-dividend date of this dividend is Wednesday, March 28th. This represents a $1.88 dividend on an annualized basis and a yield of 1.18%. Stryker’s dividend payout ratio (DPR) is currently 70.15%.

In related news, VP William E. Berry, Jr. sold 1,306 shares of Stryker stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $164.42, for a total transaction of $214,732.52. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Graham A. Mclean sold 2,984 shares of the business’s stock in a transaction on Monday, February 5th. The shares were sold at an average price of $160.53, for a total value of $479,021.52. Following the completion of the sale, the insider now owns 9,100 shares in the company, valued at $1,460,823. The disclosure for this sale can be found here. Insiders have sold 16,840 shares of company stock worth $2,749,989 over the last quarter. 7.40% of the stock is currently owned by corporate insiders.

TRADEMARK VIOLATION WARNING: “Stryker Corporation (SYK) is Marshall & Sullivan Inc. WA’s 6th Largest Position” was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this story on another domain, it was illegally stolen and republished in violation of US & international copyright & trademark laws. The legal version of this story can be read at https://www.dispatchtribunal.com/2018/02/19/stryker-corporation-syk-is-marshall-sullivan-inc-was-6th-largest-position-2.html.

Stryker Company Profile

Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK).

Institutional Ownership by Quarter for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply